Zoya Spassova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zoya Spassova has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Jose Medeiros
Gastroenterology Clinic, Rua do Carmo, 75-1° AA, 3000 Coimbra, Portugal
1 shared publication - Liliya Yordanova Boyanova
Department of Medical Microbiology, Medical University of Sofia, 2 Zdrave Str., 1431 Sofia, Bulgaria
1 shared publication - Lyudmila Boyanova
Department of Medical Microbiology, Medical University of Sofia, Sofia, Bulgaria
1 shared publication - Nayden Kandilarov
Department of General and Hepatobiliary Pancreatic Surgery, Department of Surgery, Medical Faculty, Medical University of Sofia, 15 Acad. Ivan Geshov Blvd., 1431 Sofia, Bulgaria
1 shared publication - Nikolay Katsarov
Zdraveto Hospital, 4 Maestro Kanev Str., 1618 Sofia, Bulgaria
1 shared publication - Raina Gergova
Department of Medical Microbiology, Medical Faculty, Medical University of Sofia, Zdrave str. 2, 1431 Sofia, Bulgaria
1 shared publication
Latest Publications
- Open Access
High Prevalence and Recent Increase in Multidrug-Resistant Helicobacter pylori in Bulgarian Patients: Pros and Cons of Culture-Based Susceptibility Testing
We investigated the anti-Helicobacter pylori activity of five antibiotics against isolates from 226 symptomatic adult patients during two periods (2024–2026 and 2022–2023). Antibiotic susceptibility testing (AST) was performed by MIC test strips and/or a validated disk diffusion method for tetracycline. Overall resistance was 58.8% for metronidazole, 57.1% for clarithromycin, 41.2% for levofloxacin, 9.3% for amoxicillin, and 3.5% for tetracycline. Resistance rates to 1, 2, and 3–5 antibiotics (the latter defined as multidrug resistance, MDR) were 28.8%, 33.6%, and 23.9%, respectively. In 2024–2026, metronidazole and clarithromycin resistance prevalence exceeded 62%, and four patients/isolates had quadruple/quintuple resistance. In the second period, MDR rates were twice as high as in the first period, reaching 27.1% and 29.9%, respectively. Culture-based AST can detect resistance due to various mechanisms in H. pylori and determine exact (low or high) resistance levels. Briefly, we found high resistance rates to metronidazole, clarithromycin, levofloxacin, and MDR during the last few years, possibly due to high national antibiotic consumption. Phenotypic AST is useful for choosing individualized/tailored eradication regimens in treated patients in countries/regions with high H. pylori resistance/MDR. In the era of growing antibiotic resistance, culture-based AST is important and, therefore, should not be neglected.
Open AccessHigh Prevalence and Recent Increase in Multidrug-Resistant Helicobacter pylori in Bulgarian Patients: Pros and Cons of Culture-Based Susceptibility Testing
We investigated the anti-Helicobacter pylori activity of five antibiotics against isolates from 226 symptomatic adult patients during two periods (2024–2026 and 2022–2023). Antibiotic susceptibility testing (AST) was performed by MIC test strips and/or a validated disk diffusion method for tetracycline. Overall resistance was 58.8% for metronidazole, 57.1% for clarithromycin, 41.2% for levofloxacin, 9.3% for amoxicillin, and 3.5% for tetracycline. Resistance rates to 1, 2, and 3–5 antibiotics (the latter defined as multidrug resistance, MDR) were 28.8%, 33.6%, and 23.9%, respectively. In 2024–2026, metronidazole and clarithromycin resistance prevalence exceeded 62%, and four patients/isolates had quadruple/quintuple resistance. In the second period, MDR rates were twice as high as in the first period, reaching 27.1% and 29.9%, respectively. Culture-based AST can detect resistance due to various mechanisms in H. pylori and determine exact (low or high) resistance levels. Briefly, we found high resistance rates to metronidazole, clarithromycin, levofloxacin, and MDR during the last few years, possibly due to high national antibiotic consumption. Phenotypic AST is useful for choosing individualized/tailored eradication regimens in treated patients in countries/regions with high H. pylori resistance/MDR. In the era of growing antibiotic resistance, culture-based AST is important and, therefore, should not be neglected.